2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153346
    Elironrasib
    		Inhibitor 99.65%
    Elironrasib is an orally active and covalent inhibitor of KRASG12C(ON). Elironrasib forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM.
    Elironrasib
  • HY-16659
    EHT 1864
    		Inhibitor 99.85%
    EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG.
    EHT 1864
  • HY-112842
    MBQ-167
    		Inhibitor 99.86%
    MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
    MBQ-167
  • HY-15723
    NSC 23766
    		Inhibitor 99.74%
    NSC 23766 is a cell-permeable, reversible and specific inhibitor of Rac GTPase, used for cancer treatment.
    NSC 23766
  • HY-12874
    CASIN
    		Inhibitor 99.89%
    CASIN is a selective GTPase Cdc42 inhibitor with an IC50 of 2 uM. CASIN can be used for the research of cancer.
    CASIN
  • HY-112473
    NAV-2729
    		Inhibitor 98.57%
    NAV-2729 is a dual Arf1/Arf6 activation inhibitor. ADP ribosylation factors (Arfs) are members of the Arf family of GTP-binding proteins of the Ras superfamily.
    NAV-2729
  • HY-19800
    ML-098
    		Activator 99.91%
    ML-098 (CID-7345532) is an activator of the GTP-binding protein Rab7 with an EC50 of 77.6 nM.
    ML-098
  • HY-13991
    CCG-1423
    		Inhibitor 99.94%
    CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes.
    CCG-1423
  • HY-145926
    MRTX0902
    		Inhibitor 99.75%
    MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10).
    MRTX0902
  • HY-114398
    BAY-293
    		Inhibitor 98.97%
    BAY-293, a valuable chemical probe, blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS.
    BAY-293
  • HY-14754
    Salirasib
    		Inhibitor 99.04%
    Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib
  • HY-137516
    LC-2
    		Inhibitor 98.16%
    LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines.
    LC-2
  • HY-139612
    Opnurasib
    		Inhibitor 98.71%
    Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.
    Opnurasib
  • HY-N1472
    Levistolide A
    		Inhibitor 99.26%
    Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways.
    Levistolide A
  • HY-12810
    EHop-016
    		Inhibitor 99.85%
    EHop-016 is a potent and selective Rac GTPase Rac1 and Rac3 inhibitor. EHop-016 inhibits Rac1 activity with an IC50 of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration.
    EHop-016
  • HY-N6796
    Manumycin A
    		Inhibitor 99.27%
    Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion.
    Manumycin A
  • HY-U00418
    ARS-1620
    		Inhibitor 99.62%
    ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics.
    ARS-1620
  • HY-148098
    Pan KRas-IN-1
    		Inhibitor 98.47%
    Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors.
    Pan KRas-IN-1
  • HY-114277A
    Sotorasib racemate
    		Inhibitor 98.99%
    Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research.
    Sotorasib racemate
  • HY-124306
    ML-099
    		Activator 99.75%
    ML-099 (CID-888706) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, Rab7, and Rab-2A.
    ML-099
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

K-Ras

H-Ras

N-Ras

Ras

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Ras Degraders, Inhibitors & Antagonists
Product NameK-RasH-RasN-RasRasPurity    
Sotorasib
KRAS(G12C)
   99.94%
MRTX1133
KRas G12D, Kd: 0.2 pM
   99.97%
Adagrasib
KRas G12C
   99.81%
RMC-6236
KRas G12D
   99.88%
PROTAC K-Ras Degrader-4
K-RAS
   98.23%
RMC-7977
KRAS(G12C)
H-Ras
NRAS rG4
 99.48%
Zoldonrasib
KRAS(G12D)
   99.73%
BI-3406
KRAS-SOS1, IC50: 6 nM
   99.95%
Divarasib
K-Ras(G12C), IC50: <0.01 μM
   99.31%
BI-2852
KRAS(G12C), IC50: 450 nM
KRAS(G12C), Kd: 750 nM
   99.57%
Elironrasib
KRAS(G12C)
   99.65%
MRTX0902
KRAS-SOS1, IC50: 46 nM
   99.75%
BAY-293
KRAS-SOS1, IC50: 21 nM
   98.97%
LC-2
KRAS(G12C), DC50: 0.25-0.76 μM
   98.16%
Opnurasib
KRas G12C
   98.71%
ARS-1620
KRAS(G12C)
   99.62%
Pan KRas-IN-1
KRas G12D, IC50: 9 nM
KRas G12S, IC50: 11 nM
KRas G12C, IC50: 6 nM
KRas Q61H, IC50: 12 mM
KRas G12V, IC50: 29 mM
K-Ras WT, IC50: 32 nM
   98.47%
Sotorasib racemate
KRas G12C
   98.99%
DCC-3116
KRas G12C
   99.25%
BI-2493
K-Ras WT
   99.79%
Setidegrasib
KRAS(G12D)
   99.65%
MRTX-1257
KRAS(G12C)
   99.14%
PROTAC K-Ras Degrader-1
KRAS(G12C)
   98.05%
KRAS inhibitor-3
K-Ras WT, EC50: 0.28 μM
KRAS(G12C), EC50: 0.63 μM
KRas G12D, EC50: 0.37 μM
KRas Q61H, EC50: 0.74 μM
   99.65%
ARS-853
KRAS(G12C), IC50: 2.5 μM
   98.39%
XRP44X   
Ras, IC50: 10 nM
98.09%
ARS-1323-alkyne
KRAS(G12C)
   99.59%
HRS-4642
KRas G12D, Ki: 0.083 nM
   98.06%
KRAS G12D inhibitor 14
KRas G12D, Kd: 33 nM
   99.39%
RM-018
KRAS (G12C)
KRAS (G12C/Y96D)
   98.03%
MRTX-EX185 formic
KRas G12D, IC50: 90 nM
   
SAH-SOS1A TFA
KRas G12C, EC50: 140 nM
KRas G12D, EC50: 109 nM
KRas G12V, EC50: 154 nM
KRas G12S, EC50: 155 nM
KRas Q61H, EC50: 175 nM
K-Ras WT, EC50: 106 nM
   99.16%
KRpep-2d
K-RAS
   
MCP110   
Ras
99.82%
ASP2453
KRas G12C, IC50: 40 nM
   98.28%
SOS1-IN-15
SOS1, IC50: 5 nM
   99.51%
Kobe0065 
H-Ras
  99.93%
ARS-1323
KRas G12C
   99.67%
Fulzerasib
KRAS(G12C)
   99.60%
KRAS inhibitor-10
KRas G12C
   99.92%
AZD4625
KRAS(G12C)
   99.52%
KRAS G12C inhibitor 14
KRas G12C, IC50: 18 nM
   99.00%
BI-0474
KRAS-SOS1, IC50: 7.0 nM
   99.83%
KRAS G12C inhibitor 15
KRas G12C, IC50: 5 nM
   98.47%
Sotorasib-d7
KRAS(G12C)
   
Pan-RAS-IN-4
KRas G12D
   98.53%
TH-Z835
KRAS(G12D), IC50: 1.6 μM
   99.58%
ARS-1630
KRAS(G12C)
   98.10%
RAS/RAS-RAF-IN-1   
Ras
99.81%
Spiclomazine
KRAS(G12C)
   99.95%
KRAS G12D inhibitor 3 TFA
KRas G12D, IC50: <500 nM
   98.18%
MRTX1133 formic
KRas G12D, Kd: 0.2 pM
   98.23%
KRAS G12C inhibitor 28
KRas G12C, IC50: 57 nM
   99.94%
KRas G12C inhibitor 1
KRas G12C
   
Kras4B G12D-IN-1
KRas G12D
   98.01%
CFL-137
KRAS(G12C)
   99.84%
Atrovastatin-PEG3-FITC
KRAS-PDEδ
   98.17%
KRpep-2d TFA
K-RAS
   98.11%
K-Ras G12C-IN-2
KRas G12C
   99.21%
KRAS inhibitor-6
KRAS(G12C)
   
KRAS inhibitor-8
KRAS(G12C)
   
KRAS inhibitor-7
KRAS(G12C)
   
KRAS G12C inhibitor 32
KRAS (G12C)
   
KRAS G12C inhibitor 27
KRas G12C
   
KRAS G12D inhibitor 3
KRas G12D, IC50: <500 nM
   
G12Si-1
KRas G12S
   
KRAS G12C inhibitor 5
KRas G12C
   
KRAS G12C inhibitor 18
KRas G12C
   
KRAS G12C inhibitor 13
KRas G12C
   
KRAS inhibitor-20
KRAS(G12C), IC50: <10 nM ([1])
   
KRAS inhibitor-16
KRas G12C, IC50: 0.457 μM
   
ASP6918
KRas G12C, IC50: 0.028 μM
   
KRAS G12C inhibitor 17
KRas G12C, IC50: 5 nM
   
SOS1-IN-8
SOS1-G12D, IC50: 11.6 nM
SOS1-G12V, IC50: 40.7 nM
   
KRAS inhibitor-14
KRas G12C, IC50: 0.249 μM
   
KRAS G12C inhibitor 16
KRas G12C, IC50: 97 nM
   
KRASG12C IN-12
KRas G12C
   
K-Ras-IN-3
KRas G12V, IC50: 0.371 nM
   
PROTAC K-Ras Degrader-2
KRAS G12V/RAF1, IC50: ≤200 nM
   
pan-KRAS-IN-6
KRas G12D, IC50: 9.79 nM
KRas G12V, IC50: 6.03 nM
   
pan-KRAS-IN-15
K-RAS, IC50: 1.4 nM
   
KRAS inhibitor-13
KRas G12C, IC50: 0.883 μM
   
KRAS G12C inhibitor 44
KRas G12C
   
KRAS G12C inhibitor 52
KRAS(G12C)
   
KRAS inhibitor-12
KRas G12C, IC50: 0.537 μM
   
SOS1-IN-7
SOS1-G12D, IC50: 20 nM
SOS1-G12V, IC50: 67 nM
   
KRAS G12C inhibitor 46
KRas G12C
   
pan-KRAS-IN-13
KRas G12D, IC50: 2.75 nM
KRas G12V, IC50: 2.89 nM
   
PROTAC K-Ras Degrader-3
KRas G12D
   
Spiclomazine hydrochloride
K-RAS
   
KRAS inhibitor-24
KRas G12V, IC50: < 100 nM
K-Ras WT, IC50: < 100 nM
KRas G12R, IC50: < 100 nM
   
KRAS G12C inhibitor 47
KRas G12C, IC50: 0.172 μM
   
KRAS G12D inhibitor 23
KRas G12D, IC50: 0.007 μM
   
KRAS inhibitor-15
KRas G12C, IC50: 0.954 μM
   
KRas G12C inhibitor 4
KRas G12C
   
SOS1-IN-10
KRAS G12C-SOS1, IC50: 13 nM
   
Pan-RAS-IN-6
KRas G12C, IC50: 1.3 nM
KRas G12D, IC50: 4.7 nM
KRas G12V, IC50: 0.3 nM
   
KRAS G12C inhibitor 48
KRas G12C, IC50: 639.91 nM
   
KRAS G12C inhibitor 59
KRas G12C
   
KRAS G12C inhibitor 23
KRas G12C
   
KRAS G12C inhibitor 25
KRas G12C
   
K-Ras(G12C) inhibitor 6
K-Ras(G12C)
   99.08%
pan-KRAS-IN-3
K-Ras WT
   
KRAS G12D inhibitor 20
KRas G12D
   
Anticancer agent 207  
NRAS rG4, Kd: 2.31 μM
 
MRTX849 acid
KRas G12C
   99.84%
KRAS G12C inhibitor 57
KRAS(G12C), IC50: 0.21 μM (KRAS G12C/SOS1 binding assay)
   
KRAS inhibitor-37
K-Ras WT, Kd: 0.004 nM
KRas G12D, Kd: 0.041 nM
KRas G12C, Kd: 0.019 nM
KRas G12V, Kd: 0.144 nM
   
KRAS inhibitor-35
K-RAS, : 2 nM
   
KRAS inhibitor-18
KRas G12C, IC50: 4.74 μM
   
KRAS G12C inhibitor 43
KRas G12C
   
KRAS G12C inhibitor 69
KRas G12S, IC50: 4.36 nM
   
SOS1-IN-4
KRAS-C12C/SOS1, IC50: 56 nM
   
KRAS G12C inhibitor 50
KRAS(G12C), IC50: 46.7 nM
   
KRAS G12C inhibitor 55
KRAS(G12C)
   
KRAS G12C inhibitor 51
KRAS(G12C)
   
MRTX849 ethoxypropanoic acid
KRas G12C
   
(4S)-PROTAC SOS1 degrader-1
K-RAS
   
KRas G12C inhibitor 3
KRas G12C
   
PROTAC K-Ras Degrader-6
KRas G12D, DC50: >100 nM
   
KRAS G12C inhibitor 68
KRas G12C, IC50: 7 nM
   
CFL-120
KRAS(G12C)
   ≥98.0%
K20
KRAS(G12C), IC50: 1.16 μM
   
KRAS G12D inhibitor 7
KRas G12D
   
KRAS G12C inhibitor 61
K-Ras WT
   
KRAS inhibitor-31
KRas G12D, Kd: 0.019 nM
KRas G12C, Kd: 0.019 nM
KRas G12V, Kd: 0.096 nM
   
KRAS G12D inhibitor 16
KRas G12D, IC50: 0.7 nM
   
KRAS G12C inhibitor 54
KRAS(G12C)
   
pan-KRAS-IN-16
KRas G12D
H-Ras
 
Ras
SOS1-IN-9
KRAS G12C-SOS1, IC50: 116.5 nM
   
PROTAC K-Ras Degrader-5
KRas G12D, DC50: <100 nM
   
KRAS inhibitor-17
KRas G12C, IC50: 3.37 μM
   
SOS1-IN-6
SOS1-G12D, IC50: 14.9 nM
SOS1-G12V, IC50: 73.3 nM
   
KRAS G12C inhibitor 45
KRas G12C
   
KRas G12C inhibitor 2
KRas G12C
   
PROTAC SOS1 degrader-3
SOS1
   
KRAS inhibitor-40
KRas G12C
   
TH-Z827
KRAS(G12D), IC50: 2.4 μM
   
KRAS inhibitor-34
K-RAS, : 6.4 nM
   
KRAS G12D inhibitor 22
KRas G12D, IC50: <100 nM
   
ZG1077
KRas G12C
   
SAH-SOS1A
KRas G12C, EC50: 140 nM
KRas G12D, EC50: 109 nM
KRas G12V, EC50: 154 nM
KRas G12S, EC50: 155 nM
KRas Q61H, EC50: 175 nM
K-Ras WT, EC50: 106 nM
   
SIAIS562055
SOS1, Kd: 95.9 nM
   
KRAS inhibitor-11
K-RAS
   
KRAS G12C inhibitor 26
KRas G12C
   
KRAS G12C inhibitor 53
KRAS(G12C)
   
KRASG12C IN-14
KRas G12C
   
KRASG12C IN-16
KRAS(G12C)
   
KRAS inhibitor-26
KRas G12V, IC50: <100 nM
   
KRAS inhibitor-25
KRas G12C, IC50: < 100 nM
K-Ras WT, IC50: < 100 nM
KRas G12R, IC50: < 100 nM
   
KRAS inhibitor-23
K-RAS
   
KRAS G12C inhibitor 62
KRas G12C
   
KRAS G12C inhibitor 67
KRas G12C
   
pan-KRAS ligand 1
K-RAS
   
6H05
K-Ras(G12C)
   
NHTD
K-RAS